Malaysia Drug Industry Frets Pending TPP Agreement
This article was originally published in PharmAsia News
Executive Summary
Malaysian drug manufacturers are raising concerns about adverse effects of the pending Trans Pacific Partnership Agreement, saying it would lead to increased competition and higher medicine costs.